pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

29,139 catalysts · 9,636 approval · 5,000 device 510k · 4,728 grant · 2,984 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-03: 0 catalysts2026-08-04: 0 catalysts2026-08-05: 0 catalysts2026-08-06: 0 catalysts2026-08-07: 0 catalysts2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 14 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 11 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2017-07-31×clear all
type
  • approval9,636
  • device 510k5,000
  • grant4,728
  • 8k filing2,984
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings571
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Jan 25, 2021

    6
    ›Jan 26, 2021approval2021d agoVIGABATRIN — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 26, 2021approval2021d agoVIGABATRIN — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 27, 2021approval2020d agoAMPHETAMINE SULFATE — FDA approvalAurolife Pharma LLC

    Sponsor: SUN PHARM INDS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 28, 2021approval2019d agoXARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 28, 2021approval2019d agoRETEVMO (SELPERCATINIB) — FDA approvalselpercatinib

    Sponsor: ELI LILLY AND CO. Form: CAPSULE. Route: ORAL

    full page →selpercatinib →fda approvals ↗
    ›Jan 29, 2021approval2018d agoVIGABATRIN — FDA approvalPyros Pharmaceuticals Inc.

    Sponsor: DR REDDYS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗

    Week of Feb 1, 2021

    16
    ›Feb 1, 2021approval2015d agoORILISSA (ELAGOLIX SODIUM) — FDA approvalelagolix sodium

    Sponsor: ABBVIE. Form: TABLET. Route: ORAL

    full page →elagolix sodium →fda approvals ↗
    ›Feb 1, 2021approval

    Week of Feb 8, 2021

    18
    ›Feb 8, 2021approval2008d agoDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval(daratumumab + hyaluronidase (human recombinant))

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →(daratumumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Feb 8, 2021

    Week of Feb 15, 2021

    10
    ›Feb 16, 2021approval2000d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: AUROLIFE PHARMA LLC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval
    ← prev
    page 52 of 583
    next →
    2015d ago
    ORILISSA (ELAGOLIX SODIUM) — FDA approvalelagolix sodium

    Sponsor: ABBVIE. Form: TABLET. Route: ORAL

    full page →elagolix sodium →fda approvals ↗
    ›Feb 1, 2021approval2015d agoORILISSA (ELAGOLIX SODIUM) — FDA approvalelagolix sodium

    Sponsor: ABBVIE. Form: TABLET. Route: ORAL

    full page →elagolix sodium →fda approvals ↗
    ›Feb 1, 2021approval2015d agoLEUPROLIDE ACETATE — FDA approvalLEUPROLIDE ACETATE

    Sponsor: SANDOZ. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →LEUPROLIDE ACETATE →fda approvals ↗
    ›Feb 1, 2021approval2015d agoLEUPROLIDE ACETATE — FDA approvalLEUPROLIDE ACETATE

    Sponsor: SANDOZ. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →LEUPROLIDE ACETATE →fda approvals ↗
    ›Feb 2, 2021approval2014d agoMORPHINE SULFATE — FDA approvalKapanol

    Sponsor: ACTAVIS ELIZABETH. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →Kapanol →fda approvals ↗
    ›Feb 2, 2021approval2014d agoNIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: KRAMER. Form: SHAMPOO. Route: TOPICAL

    full page →fda approvals ↗
    ›Feb 2, 2021approval2014d agoZIPRASIDONE MESYLATE — FDA approvalZIPRASIDONE MESYLATE

    Sponsor: GLAND. Form: POWDER. Route: INTRAMUSCULAR

    full page →ZIPRASIDONE MESYLATE →fda approvals ↗
    ›Feb 2, 2021approval2014d agoZIPRASIDONE MESYLATE — FDA approvalZIPRASIDONE MESYLATE

    Sponsor: GLAND. Form: POWDER. Route: INTRAMUSCULAR

    full page →ZIPRASIDONE MESYLATE →fda approvals ↗
    ›Feb 4, 2021approval2012d agoADRENACLICK (EPINEPHRINE) — FDA approvalViatris Inc

    Sponsor: IMPAX. Form: INJECTABLE. Route: INTRAMUSCULAR, SUBCUTANEOUS

    full page →fda approvals ↗
    ›Feb 4, 2021approval2012d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: PH HEALTH. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 4, 2021approval2012d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: PH HEALTH. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 4, 2021approval2012d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: PH HEALTH. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 4, 2021approval2012d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Feb 5, 2021approval2011d agoCHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE (AMITRIPTYLINE HYDROCHLORIDE) — FDA approvalAlgoTherapeutix SAS

    Sponsor: TP ANDA HOLDINGS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Feb 5, 2021approval2011d agoCHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE (AMITRIPTYLINE HYDROCHLORIDE) — FDA approvalAlgoTherapeutix SAS

    Sponsor: TP ANDA HOLDINGS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    approval
    2008d ago
    BUPRENORPHINE HYDROCHLORIDE — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: ACTAVIS ELIZABETH. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Feb 8, 2021approval2008d agoMETHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: SOLUTION. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 8, 2021approval2008d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Feb 8, 2021approval2008d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: ASCENT PHARMS INC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 8, 2021approval2008d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 8, 2021approval2008d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 8, 2021approval2008d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 9, 2021approval2007d agoFINGOLIMOD HYDROCHLORIDE — FDA approvalFINGOLIMOD HYDROCHLORIDE

    Sponsor: BIOCON LTD. Form: CAPSULE. Route: ORAL

    full page →FINGOLIMOD HYDROCHLORIDE →fda approvals ↗
    ›Feb 9, 2021approval2007d agoLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalcemiplimab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INTRAVENOUS

    full page →cemiplimab →fda approvals ↗
    ›Feb 9, 2021approval2007d agoLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalcemiplimab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INTRAVENOUS

    full page →cemiplimab →fda approvals ↗
    ›Feb 10, 2021approval2006d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Feb 10, 2021approval2006d agoDEPAKOTE (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: CAPSULE, DELAYED REL PELLETS. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Feb 10, 2021approval2006d agoDEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Feb 10, 2021approval2006d agoDEPAKOTE (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Feb 10, 2021approval2006d agoIDARUBICIN HYDROCHLORIDE — FDA approvalIDARUBICIN HYDROCHLORIDE

    Sponsor: PFIZER. Form: SOLUTION. Route: INTRAVENOUS

    full page →IDARUBICIN HYDROCHLORIDE →fda approvals ↗
    ›Feb 11, 2021approval2005d agoDEPO-MEDROL (METHYLPREDNISOLONE ACETATE) — FDA approvalMETHYLPREDNISOLONE ACETATE

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →METHYLPREDNISOLONE ACETATE →fda approvals ↗
    ›Feb 11, 2021approval2005d agoEVKEEZA (EVINACUMAB-DGNB) — FDA approvalevinacumab

    Sponsor: REGENERON PHARMACEUTICALS. Form: SOLUTION. Route: INJECTION

    full page →evinacumab →fda approvals ↗
    2000d ago
    OXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: AUROLIFE PHARMA LLC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval2000d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: AUROLIFE PHARMA LLC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval2000d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval2000d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval2000d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval2000d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Feb 16, 2021approval2000d agoMETHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: ELITE LABS INC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval2000d agoMETHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: ELITE LABS INC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Feb 16, 2021approval2000d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    $LLY1185.71-0.52%
    $ABBV246.04+0.89%
    $ABBV246.04+0.89%
    $VTRS16.43+0.86%
    $ABBV246.04+0.89%
    $IGC0.2670+0.41%
    $REGN784.36+1.59%
    $REGN784.36+1.59%
    $ABBV246.04+0.89%
    $ABBV246.04+0.89%
    $ABBV246.04+0.89%
    $PFE26.76+2.14%
    $PFE26.76+2.14%
    $IGC0.2670+0.41%
    $REGN784.36+1.59%